NCT06218134View on ClinicalTrials.gov

Evaluate the Safety and Potential Efficacy of Human Wharton's Jelly-derived Mesenchymal Stem Cells With Charcot-Marie-Tooth Disease Type 1E

NANot yet recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Charcot-Marie-Tooth Disease, Type 1
Interventions
BIOLOGICAL

human Wharton's jelly-derived mesenchymal stem cells

human Wharton's jelly-derived mesenchymal stem cells(product name: EN001)

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT06218134 - Evaluate the Safety and Potential Efficacy of Human Wharton's Jelly-derived Mesenchymal Stem Cells With Charcot-Marie-Tooth Disease Type 1E | Biotech Hunter | Biotech Hunter